{"public_id":"cl_cec7b015523bb636f0f8cf3899dfcd95","status":"active","superseded_by_public_id":null,"corpus_id":44162853,"text":"Quality of life uncertainties and trial patient population uncertainties were discussed frequently but rarely occurred in the more uncertain appraisals.","confidence":0.92,"paper":{"corpus_id":44162853,"title":"Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals","url":"https://sah.borca.ai/papers/44162853"},"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.92,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_298a19d3ae674989d0f57cce8688d74f","name":"more uncertain appraisals","description":"Cancer drug appraisals characterized by a higher inferred level of uncertainty in the committee's decision context.","types":["appraisal category"],"url":"https://sah.borca.ai/concepts/co_298a19d3ae674989d0f57cce8688d74f"},{"public_id":"co_5b4e8c165fc2e6746f121b5ea13db866","name":"quality of life","description":"Patient health-related wellbeing outcomes considered in the economic and clinical appraisal of cancer drugs.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_5b4e8c165fc2e6746f121b5ea13db866"},{"public_id":"co_c1042510ba2525fe0454d44f0b9fc403","name":"patient population in the trial","description":"The group of patients enrolled in a clinical trial and considered for its relevance to the appraised population.","types":["study population"],"url":"https://sah.borca.ai/concepts/co_c1042510ba2525fe0454d44f0b9fc403"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_cec7b015523bb636f0f8cf3899dfcd95"}